Revolution Medicines began shipping daraxonrasib to physicians and patients under an early access program authorized by the FDA, CEO Mark Goldsmith said during an ASCO-linked briefing. The therapy is still unapproved, but Revolution reported strong Phase 3 results earlier this year and said demand accelerated after the initial readout in mid-April. The early access effort is designed to route the experimental pill to treating sites while the company continues regulatory and clinical work. Goldsmith framed the program as a mechanism to deliver the investigational treatment to patients actively seeking options. The update follows the trial’s reported outcome in which patients treated with daraxonrasib lived nearly twice as long as those given standard chemotherapy, a benchmark described as unprecedented in the pancreatic cancer setting.